曲妥珠单抗耐药的机制和对策研究进展

Advances in research on the mechanisms of trastuzumab resistance and strategies to overcome the resistance

曲妥珠单抗是人表皮生长因子受体2(HER2)过表达乳腺癌患者的重要治疗手段之一。但即使是HER2高表达或是基因扩增的患者,曲妥珠单抗单药的有效率也仅为12%～34%,中位缓解期约9个月,许多患者在接受治疗的12个月内出现疾病进展。对曲妥珠单抗的耐药机制进行研究,有助于我们为曲妥珠单抗耐药的患者寻找新的治疗药物和方法。

Trastuzumab is one of the most important drugs for HER2 overexpressing breast cancer patients. However, even for these patients, the objective response rates to trastuzumab monotherapy are 12%-34%, and the median duration is about 9 months. Many patients progress within 12 months. Study of the mechanisms of resistance to trastuzumab will help us fi nd some new drugs and methods to overcome or delay the resistance.